Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn’s Disease Patients: Results from the CONNECT Study

Chang Mo Moon1, Sung-Ae Jung1*, Seong-Eun Kim1, Hyun Joo Song2, Yunho Jung3, Byong Duk Ye4, Jae Hee Cheon5, You Sun Kim6, Young-Ho Kim7, Joo Sung Kim8, Dong Soo Han9, CONNECT study group

1 Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Republic of Korea, 2 Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Republic of Korea, 3 Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan, Republic of Korea, 4 Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea, 5 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, 6 Department of Internal Medicine, Inje University College of Medicine, Seoul Paik Hospital, Seoul, Republic of Korea, 7 Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 8 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 9 Department of Internal Medicine, Hanyang University College of Medicine, Guri Hospital, Guri, Republic of Korea

¶ Membership of the CONNECT study group is listed in the Acknowledgments.

* jassa@ewha.ac.kr

Abstract

Diagnostic delay frequently occurs in Crohn’s disease (CD) patients because of diagnostic limitations. However, diagnostic delay and its related factors remain poorly defined. Therefore, we aimed to identify the predictors associated with diagnostic delay and to evaluate the impact of diagnostic delay on clinical course in a Korean CD patient cohort. We performed a multicenter retrospective analysis of 1,047 CD patients registered in the Crohn’s Disease Clinical Network and Cohort study in Korea. The mean interval of diagnostic delay was 16.0 ± 33.1 months. Multivariate analysis showed that older age at diagnosis (≥40 years) (p = 0.014), concomitant upper gastrointestinal (UGI) disease (p = 0.012) and penetrating disease behavior at diagnosis (p = 0.001) were positively associated with long diagnostic delay (≥18 months). During the longitudinal follow-up, long diagnostic delay was independently predictive of further development of intestinal stenosis (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.07–1.93; p = 0.017), internal fistulas (HR, 1.62; 95% CI, 1.12–2.33; p = 0.011), and perianal fistulas (HR, 1.38; 95% CI, 1.06–1.80; p = 0.016). However, as for the risk of abscess formation, bowel perforation, and CD-related abdominal surgery, no significant association with diagnostic delay was observed. Older age at diagnosis, UGI involvement, and penetrating behavior are associated with long diagnostic delay in Korean CD patients. Moreover, diagnostic delay is associated with an increased risk of CD-related complications such as intestinal stenosis, internal fistulas, and perianal fistulas.
Introduction

Crohn’s disease (CD) is a chronic relapsing and destructive inflammatory condition of the gastrointestinal tract that progresses to bowel damage related to impaired functioning. When CD patients are followed over time, patients with inflammatory behavior tend to experience structural destruction of the bowel, such as stricture or internal fistulas [1,2]. Recently, studies have shown that early diagnosis and intensive treatment of CD are necessary to prevent bowel damage and unexpected surgery in patients [3–5]. In addition, studies reported that early intensive treatment with immunomodulators or biologics showed superior clinical outcomes to conventional treatment in newly diagnosed CD patients [3,4].

However, a long diagnostic delay occurs in a considerable number of CD patients [6,7] because of the unspecific symptoms of CD and unsatisfactory diagnostic accuracy of tests for CD. Considering that intestinal inflammation occurs after the onset of the first symptoms in CD patients, reducing diagnostic delay could have clinical implications in real clinical practice. Identification of factors associated with CD can allow early treatment and prevent an unfavorable course in CD patients. Several studies have evaluated clinical factors associated with diagnostic delay in Western patients [8,9] and few studies have examined these factors in Eastern patients [10]. Considering the significant differences in the epidemiologic and clinical features of CD according to ethnicities and environmental factors [11–13], diagnostic delay and its associated factors may differ with countries.

Therefore, the present study aimed to evaluate the clinical factors associated with a long diagnostic delay in Korean CD patients. In addition, we investigated the influence of diagnostic delay on the clinical course of CD, including the occurrence of complications, in our CD patient cohort.

Materials and Methods

Study subjects

This study analyzed clinical data obtained from 1,047 Korean CD patients diagnosed between January 1, 2000 to December 31, 2008. All data were retrieved from the Crohn’s Disease Clinical Network and Cohort (CONNECT) study, a multicenter retrospective cohort study of CD patients, which was conducted in 30 university hospitals and 2 local hospitals nationwide in Korea [14]. All patients were diagnosed and treated by inflammatory bowel disease (IBD) specialists who are members of the Korean Association for the Study of Intestinal Diseases. Diagnosis of CD was made on the basis of clinical, endoscopic, radiological, and histopathologic characteristics of the patients [15,16]. The following patients were excluded from this study: those who were diagnosed with or suspected to have intestinal tuberculosis, intestinal Behçet’s disease, or indeterminate colitis; those who were followed up for < 6 months; and those with incomplete medical records. Because this is retrospective observational study, written consent could not be obtained. But, all clinical data were analyzed anonymously to protect patient privacy. This study was approved by the Institutional Review Board of Ewha Womans University Mokdong Hospital (EUMC 2014-10-034) and conducted in accordance with the ethical guidelines of the Declaration of Helsinki.

Data collection, definition and assessment of clinical outcomes

The demographic and clinical characteristics including age at first diagnosis, gender, family history of IBD, history of previous abdominal surgery, and follow-up duration were analyzed. Follow-up duration was defined as the period from the CD diagnosis to the latest follow-up. Disease location and behavior at initial presentation were classified according to the Montreal
Classification [17]. Prescribed medications including 5-aminosalicylic acid, antibiotics, oral corticosteroids, azathioprine/6-mercaptopurine, methotrexate, and anti-tumor necrosis factor α (anti-TNFα) were also recorded. Data were obtained by reviewing the medical records of the CD patients at each institute. Diagnostic delay was defined as the time interval from the onset of the first symptoms to the establishment of the CD diagnosis. The first CD-related symptoms and their onset were evaluated in all patients by a review of the physician’s notes. Specific symptoms of CD included bloody diarrhea, chronic or recurrent diarrhea or abdominal pain accompanied by noticeable weight loss, general weakness, and fever. To investigate the association between clinical factors and diagnostic delay in CD patients, a time interval of ≥18 months was defined as a “long diagnostic delay.” Further, to evaluate the clinical effects of the diagnostic delay, the primary outcome was measured as the time to development of the following CD-related complications: intestinal stenosis, internal fistula, perianal fistula, abscess formation, bowel perforation, and disease-related abdominal surgery. Internal fistulas included all fistulas from the bowel to other organs, such as entero-enteric, enterocutaneous, enterovesical, and enterourinary fistulas, except perianal fistulas. Patients who underwent operation for the treatment of perianal disease and strictureplasty were excluded from the analysis. The diagnostic delay interval was categorized as follows: <3 months, 3–6 months, 6–18 months, and ≥18 months.

Statistical analysis

We first performed two sets of univariate and multivariate analyses to identify the clinical factors associated with the long diagnostic delay in CD patients. In these analyses, the dependent variable was diagnostic delay and the independent variables were as follows: age (<40 or ≥40 years), gender, family history of IBD, any ileal involvement, concomitant upper gastrointestinal (UGI) disease, and disease behavior at the time of diagnosis. The chi-square or Fisher’s exact test was used for the univariate analysis and a multiple logistic regression model adjusted for the aforementioned variables was used for the multivariate analysis.

Further, a Kaplan-Meier survival model and log-rank test were used to evaluate the clinical variables associated with the outcomes of interest (intestinal stenosis, internal fistula, perianal fistula, abscess formation, bowel perforation, and CD-related abdominal surgery). In addition, a multivariate Cox proportional hazards regression analysis including age, gender, family history of IBD, any ileal involvement, UGI involvement, and the diagnostic delay interval was performed to assess the impact of diagnostic delay on the disease course. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated as measures of the correlation between the clinical variables and outcomes of interest. Values of $p < 0.05$ were considered statistically significant. Statistical analyses were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA).

Results

Baseline characteristics of patients

This study included 1,047 Korean CD patients. The mean age at first diagnosis was 27.7 ± 12.3 years, and the male-to-female ratio was 2.61:1. Regarding disease location at diagnosis, ileocolonic disease (613 patients, 58.5%) was the most common, and UGI involvement was observed in 95 (9.1%) patients. Disease behavior was inflammatory in 855 (81.7%), strictureing in 104 (9.9%), and penetrating in 88 (8.4%) patients. Of the patients, 748 (71.4%) were on immunomodulators and 304 (29.0%) were prescribed anti-TNFα agents. During the follow-up period, 228 (21.8%) patients underwent abdominal surgery owing to CD-related problems. The mean length of the diagnostic delay was 16.0 ± 33.1 (range: 0–412.4) months. On the basis of the
diagnostic delay interval, 471 (45.0%) patients were categorized in <3-month delay group, whereas 224 (21.4%) patients were categorized in ≥18-month delay group. The mean follow-up duration was 89.5 ± 36.1 (range: 6.0–173.3) months. The baseline demographic and clinical features of the study population are outlined in Table 1.

Clinical factors associated with long diagnostic delay in CD patients

We performed univariate and multivariate analyses to evaluate the association between the clinical factors and long diagnostic delay. In CD patients with a diagnostic delay interval of <18 months, compared to those with a diagnostic delay interval of ≥18 months, univariate analysis showed that older age at diagnosis ($p = 0.006$), concomitant UGI involvement ($p = 0.011$), and disease behavior at diagnosis ($p = 0.004$) were associated with long diagnostic delay. Subsequently, we performed a multivariate logistic regression analysis including all clinically significant variables. This analysis identified the following variables as the independent

Table 1. Baseline demographics of study subjects (n = 1,047).

| Demographic characteristics                                      | 27.7 ± 12.3 (7.8–87.8) |
|------------------------------------------------------------------|------------------------|
| Age at diagnosis (years)$^a$                                     | 2.61:1 (757:290)       |
| Gender (male:female)                                             | 23 (2.2)               |
| Family history of IBD (%)                                        | 154 (14.7)             |
| History of prior abdominal surgery (%)                          | 855 (81.7)             |
| Disease location at diagnosis (%)$^b$                            | 195 (18.6)             |
| Ileum only (L1)                                                  | 613 (58.5)             |
| Colon only (L2)                                                  | 239 (22.8)             |
| Ileocolon (L3)                                                   | 104 (9.9)              |
| Concomitant UGI disease (L4)                                     | 88 (8.4)               |
| Concomitant perianal disease (P)                                 | 292 (27.9)             |
| Disease behavior at diagnosis (%)$^b$                            | 748 (71.4)             |
| Inflammatory (B1)                                                | 12 (1.1)               |
| Stricturing (B2)                                                 | 304 (29.0)             |
| Penetrating (B3)                                                 | 1,025 (97.9)           |
| Concomitant perianal disease (P)                                 | 588 (56.2)             |
| Medication (%)                                                   | 656 (62.7)             |
| 5-ASA                                                            | 672 (64.2)             |
| Antibiotics                                                      | 748 (71.4)             |
| Oral corticosteroids                                             | 12 (1.1)               |
| AZA/6-MP                                                         | 201 (19.2)             |
| Concomitant abdominal surgery (%)                                | 471 (45.0)             |
| Interval of diagnostic delay (%)                                 | 228 (21.8)             |
| <3 months                                                        | 151 (14.4)             |
| 3–6 months                                                       | ≥18 months             |
| 6–18 months                                                      | 224 (21.4)             |
| Follow-up duration (months)$^a$                                  | 89.5 ± 36.1 (6.0–173.3) |

IBD, inflammatory bowel disease; UGI, upper gastrointestinal; 5-ASA, 5-aminosalicylic acid; AZA/6-MP, azathioprine/6-mercaptopurine; MTX, methotrexate; anti-TNFα, anti-tumor necrosis factor α; CD, Crohn’s disease.

$^a$Mean ± standard deviation.
$^b$Disease location and behavior were determined according to the Montreal classification.

doi:10.1371/journal.pone.0144390.t001
risk factors for long diagnostic delay: older age at diagnosis (≥40 years) (odds ratio [OR] = 1.64; 95% CI, 1.11–2.42, p = 0.014), UGI disease (OR = 1.83; 95% CI, 1.14–2.93, p = 0.012), and penetrating disease behavior (OR = 2.22; 95% CI, 1.38–3.57, p = 0.001) (Table 2).

Diagnostic delay was a predictive risk factor for intestinal complications in CD patients

During longitudinal follow-up, disease-related complications developed in some CD patients in this study. Intestinal stenosis, internal fistula, perianal fistula, abscess formation, and intestinal perforation occurred in 262 (25.0%), 168 (16.0%), 390 (37.2%), 133 (12.7%), and 50 (4.8%) Table 2. Clinical factors associated with long diagnostic delay (≥ 18 months) in Crohn's disease.

|                                | Diagnostic delay > 18 months (N = 283) | Diagnostic delay < 18 months (N = 978) | P value | OR     | 95% CI | P value |
|--------------------------------|----------------------------------------|----------------------------------------|---------|--------|--------|---------|
| Age at diagnosis (%)           |                                        |                                        |         |        |        |         |
| ≥ 40 years                     | 46 (29.7)                              | 109 (70.3)                             | 0.006   | 1.64   | 1.11–2.42 | 0.014   |
| < 40 years                     | 178 (20.0)                             | 714 (80.0)                             |         |        | 1      | (reference) |
| Gender                         |                                        |                                        |         |        |        |         |
| Female                         | 72 (24.8)                              | 218 (75.2)                             | 0.094   | 1.30   | 0.94–1.81 | 0.114   |
| Male                           | 152 (20.1)                             | 605 (79.9)                             |         |        | 1      | (reference) |
| Family history of IBD (%)      |                                        |                                        |         |        |        |         |
| Yes                            | 8 (34.8)                               | 15 (65.2)                              | 0.113   | 1.99   | 0.82–4.87 | 0.130   |
| No                             | 216 (21.1)                             | 808 (78.9)                             |         |        | 1      | (reference) |
| Disease location at diagnosis (%)<sup>a</sup> |                                        |                                        |         |        |        |         |
| Any ileal involvement          | 180 (21.1)                             | 672 (78.9)                             | 0.659   | 0.87   | 0.59–1.27 | 0.462   |
| No involvement of ileum        | 44 (22.6)                              | 151 (77.4)                             |         |        | 1      | (reference) |
| Concomitant UGI disease (L4)    |                                        |                                        |         |        |        |         |
| Yes                            | 30 (31.6)                              | 65 (68.4)                              | 0.011   | 1.83   | 1.14–2.93 | 0.012   |
| No                             | 194 (20.4)                             | 758 (79.6)                             |         |        | 1      | (reference) |
| Disease behavior at diagnosis (%)<sup>a</sup> |                                        |                                        |         |        |        |         |
| Inflammatory (B1)              | 170 (19.9)                             | 685 (80.1)                             | 0.004   | 1      | 1      | (reference) |
| Stricturing (B2)               | 23 (22.1)                              | 81 (77.9)                              |         |        | 1.03   | 0.62–1.70 | 0.917   |
| Penetrating (B3)               | 31 (35.2)                              | 57 (64.8)                              | 2.22    | 1.38–3.57 | 0.001   |

OR, Odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.

<sup>a</sup>Disease location and behavior were determined according to the Montreal classification.

doi:10.1371/journal.pone.0144390.t002
patients, respectively. To evaluate the impact of diagnostic delay on the clinical course in CD patients, associations between clinical factors including the diagnostic delay interval and the development of these complications were analyzed using univariate (Kaplan-Meier survival model) and multivariate (Cox proportional hazards regression model) models.

In this study, long diagnostic delay (>18 months) was independently associated with an increased risk of intestinal stenosis (HR = 1.43; 95% CI, 1.07–1.93, p = 0.017). Moreover, a significant association was observed between ileal involvement and the risk of intestinal stenosis (HR = 1.54; 95% CI, 1.08–2.21, p = 0.017) (Table 3). Similarly, diagnostic delay and ileal involvement were significantly associated with an increased risk of internal fistulas (HR = 1.62; 95% CI, 1.12–2.33, p = 0.011 and HR = 1.89; 95% CI, 1.17–3.06, p = 0.009, respectively) (Table 4). In addition, long diagnostic delay (>18 months) was independently predictive of further development of perianal fistulas (HR = 1.38; 95% CI, 1.06–1.80, p = 0.016) (Table 5).

However, no significant association was observed between long diagnostic delay and other complications such as abscess formation and intestinal perforation. Multivariate analysis showed that no clinical factors were associated with a risk of abscess formation (S1 Table). A significant association was observed between intestinal perforation and the male gender (HR = 2.16, p = 0.047), but not between intestinal perforation and diagnostic delay (S2 Table). As for the first CD-related abdominal surgery, no significant association was observed between long diagnostic delay and the risk of abdominal surgery. Other factors such as ileal involvement

### Table 3. Predictive clinical factors associated with the risk of intestinal stenosis in Korean patients with Crohn’s disease.

| Age at diagnosis (%) | Univariate analysis<sup>a</sup> | Multivariate analysis<sup>b</sup> |
|----------------------|----------------------------------|----------------------------------|
| 5-year cumulative rate (%) | P value | HR | 95% CI | P value |
| < 40 years | 21.3 | 0.81 | 0.58–1.13 | 0.211 |
| ≥ 40 years | 27.5 | 1 (Ref) |
| Gender | | | | |
| Male | 23.5 | 1.25 | 0.94–1.66 | 0.121 |
| Female | 19.1 | 1 (Ref) |
| Family history of IBD (%) | | | | |
| Yes | 31.2 | 1.46 | 0.75–2.84 | 0.272 |
| No | 22.0 | 1 (Ref) |
| Disease location at diagnosis (%) | | | | |
| Any ileal involvement | 23.3 | 1.54 | 1.08–2.21 | 0.017 |
| No involvement of ileum | 17.5 | 1 (Ref) |
| Concomitant UGI disease (L4) | | | | |
| Yes | 30.0 | 1.26 | 0.86–1.84 | 0.242 |
| No | 21.5 | 1 (Ref) |
| Interval of diagnostic delay (%) | | | | |
| < 3 months | 21.2 | 1 (Ref) |
| 3–6 months | 19.2 | 0.87 | 0.58–1.29 | 0.477 |
| 6–18 months | 21.0 | 0.97 | 0.69–1.36 | 0.846 |
| ≥ 18 months | 27.7 | 1.43 | 1.07–1.93 | 0.017 |

HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.

<sup>a</sup>calculated by a Kaplan-Meier survival model.

<sup>b</sup>analyzed by a multivariate Cox proportional hazards regression model.

<sup>c</sup>Disease location and behavior were determined according to the Montreal classification.

doi:10.1371/journal.pone.0144390.t003
(HR = 1.66, p = 0.014), strictureing (HR = 4.83, p < 0.001), and penetrating behavior (HR = 5.99, p < 0.001) at diagnosis were associated with abdominal surgery (S3 Table).

**Discussion**

This nationwide CD cohort study in Korea showed that long diagnostic delay was significantly associated with an increased risk of CD-related complications, such as intestinal stenosis, internal fistulas, and perianal fistulas. Up to date, few studies have evaluated the impact of the diagnostic delay of CD. A Swiss IBD cohort study reported that a long diagnostic delay was associated with the further development of bowel stenosis and intestinal surgery [18]. These results may be closely related to the sustained changes in the disease behavior of CD. Inflammatory disease behavior is dominant during the early stages of CD, whereas patients tend to develop intestinal complications such as strictures or fistulas as time passes [1,2]. In a study by Louis et al., disease behavior changed in 45.9% of the CD patients over 10 years, and the change from inflammatory disease to either strictureting or penetrating disease was the most common (27.1% and 29.4%, respectively) [2]. Accordingly, it is speculated that a long diagnostic delay can represent a treatment gap that causes disease progression to intestinal complications. Therefore, the diagnostic delay of CD is an important issue because strictureting and penetrating disease behavior are both independent risk factors for an unfavorable disease course, such as CD-related abdominal surgery [19,20].
In addition, in the last two decades, several studies reported that an early intensive treatment with immunosuppressive agents or biologics showed better clinical outcomes than conventional treatment in newly diagnosed CD patients [3,4]. In this regard, an international group of IBD experts suggested that the concept of “early CD” be used in future clinical trials of CD [21]. They defined early CD as a disease duration of \( \leq 18 \) months measured from the first diagnosis, with no current/previous treatment with immunomodulators or biologics. Regarding the early use of disease-modifying agents, a trial, in which 133 moderate-severe CD patients were randomized to receive either conventional treatment (step-up approach) or early combined treatment with azathioprine and infliximab (top-down approach), reported that the combined immunosuppression group (top-down) showed a greater effectiveness in clinical remission than the step-up group at week 26 (60.0% vs. 35.9%, \( p = 0.0062 \)) [3]. The impact of disease duration on treatment response was also suggested in the PRECISE 2 study. This study reported that at week 26, the clinical response rate with certolizumab pegol in CD patients with a diagnosis < 1 year (89.5%) was better than that in those with a diagnosis \( \geq 5 \) years (57.3%, \( p < 0.05 \)) [4]. Furthermore, mucosal healing, which is a promising surrogate end point for estimating disease course early, was achieved more frequently in CD patients receiving scheduled infliximab treatment than in those receiving episodic treatment for CD [22]. Taken together, the earlier CD was diagnosed from the first CD-related symptoms, the earlier intensive treatment with disease-modifying drugs was given to more CD patients, and the better was the disease course.

Table 5. Predictive clinical factors associated with the risk of perianal fistula in Korean patients with Crohn’s disease.

|                                    | Univariate analysis\(^a\) | Multivariate analysis\(^b\) |
|------------------------------------|---------------------------|-----------------------------|
|                                    | 5-year cumulative rate (%) | \( P \) value | HR | 95% CI | \( P \) value |
| Age at diagnosis (%)               |                           | \( < 0.001 \) | 3.15 | 2.05–4.86 | \( < 0.001 \) |
| < 40 years                         | 39.1                      | \( < 0.001 \) | 3.15 | 2.05–4.86 | \( < 0.001 \) |
| \( \geq 40 \) years                | 14.5                      | \( \geq 18 \) months        | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Gender                             |                           | 0.152                      | 1.12 | 0.89–1.41 | 0.339 |
| Male                               | 37.0                      |                           | 1.12 | 0.89–1.41 | 0.339 |
| Female                             | 31.3                      |                           | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Family history of IBD (%)          |                           | 0.136                      | 1.46 | 0.82–2.61 | 0.198 |
| Yes                                | 47.8                      |                           | 1.46 | 0.82–2.61 | 0.198 |
| No                                 | 35.1                      |                           | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Disease location at diagnosis (%)\(^c\) |                           | 0.557                      | 1.03 | 0.80–1.34 | 0.808 |
| Any ileal involvement              | 35.8                      |                           | 1.03 | 0.80–1.34 | 0.808 |
| No involvement of ileum            | 33.9                      |                           | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Concomitant UGI disease (L4)       |                           | 0.359                      | 1.12 | 0.80–1.56 | 0.523 |
| Yes                                | 40.1                      |                           | 1.12 | 0.80–1.56 | 0.523 |
| No                                 | 35.0                      |                           | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| Interval of diagnostic delay (%)   |                           | 0.005                      | 1.42 | 1.06–1.90 | 0.020 |
| < 3 months                         | 29.9                      |                           | 1.42 | 1.06–1.90 | 0.020 |
| 3–6 months                         | 40.4                      |                           | 1.42 | 1.09–1.85 | 0.009 |
| 6–18 months                        | 40.7                      |                           | 1.42 | 1.09–1.85 | 0.009 |
| \( \geq 18 \) months              | 39.0                      |                           | 1.38 | 1.06–1.80 | 0.016 |

HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UGI, upper gastrointestinal.

\(^a\)calculated by a Kaplan-Meier survival model.

\(^b\)analyzed by a multivariate Cox proportional hazards regression model.

\(^c\)Disease location and behavior were determined according to the Montreal classification.

doi:10.1371/journal.pone.0144390.005
Interestingly, in this study, the impact of long diagnostic delay was observed on the occurrence of intestinal stenosis and internal fistula among the CD-related intestinal complications. This phenomenon can be explained by the significant association between the occurrence of intestinal stenosis and internal fistulas. Although the exact pathogenesis of developing an internal fistula is still unclear, a previous study showed that most internal fistulas occur within or close (at the proximal end) to intestinal stenosis [23]. In addition, a significant association was observed between a long diagnostic delay and occurrence of a perianal fistula. The occurrence of a perianal fistula is a clinical predictive factor for disabling disease and disease-related surgery [24–26] as well as a clinical outcome of an unfavorable disease course. These factors may cause this significant association. On the other hand, there was no significant association between long diagnostic delay and the risk of abdominal surgery. These findings can be explained by several factors. First, not all intestinal stenosis or fistulas require surgery. One researcher reported that the intestinal fistula in itself is not regarded an indication for surgery, although it frequently occurs in CD patients [27]. In general, fistulas accompanied by intestinal obstructions or abscesses, or which cause intestinal malabsorption or communicate with the genitourinary tract are indications for surgery. As for intestinal stenosis, abdominal surgery is only one of the therapeutic options. The other options are anti-inflammatory medication and endoscopic balloon dilation [28,29]. Endoscopic dilation is an effective and safe alternative to surgical management, especially in short stenosis [29]. Additionally, the present study did not include strictureplasty, a surgery used for intestinal stenosis. Second, the cumulative rate of first CD-related abdominal surgery in Korean CD patients was much lower than that in Western patients [13,30]. The cumulative operation rate could be influenced by differences of ethnicity, environment, or attitudes of physicians and patients to surgery. Korean patients might be more unwilling to undergo intestinal resection than Westerners, possibly because Korea is a country based on Confucian values [30,31]. These factors can partially explain why we found no significant association between long diagnostic delay and the risk of abdominal surgery in this study.

Our study also evaluated the clinical factors associated with a long diagnostic delay in CD patients. Consequently, older age at diagnosis (≥40 years), concomitant UGI disease, and penetrating disease behavior were identified as independent risk factors for long diagnostic delay (≥18 months). Among them, an increased risk of diagnostic delay in older CD patients might mainly depend on physician’s delay in diagnosing CD. Considering that the usual onset of CD is at a younger age and there is still a relatively low prevalence of CD in Korea [13,32], it is speculated that physicians tend to not list CD in their differential diagnosis when they meet older patients with CD symptoms. The increased risk of diagnostic delay in patients with concomitant UGI disease may be partially explained by the fact that clinical symptoms of CD are similar to those with functional gastrointestinal disorders [33] or other UGI diseases including peptic ulcer or dyspepsia. In particular, peptic ulcer is a significant concern for Koreans, in whom the prevalence of Helicobacter pylori (H. pylori) infection for individuals older than 16 years is 59.6% [34]. H. pylori has been reported to play a causal role in various conditions such as peptic ulcer disease [35], gastroesophageal reflux disease [36], and functional dyspepsia [37]. Additionally, UGI disease in CD, namely, the Montreal L4 category also includes the involvement in the proximal part of the small bowel as well as esophageal and gastroduodenal involvement [15,38]. The diagnosis of small bowel CD, especially proximal small bowel, may be challenging because of various nonspecific symptoms and limitations of detection with conventional examinations [39]. Regarding the association between disease behavior and diagnostic delay, the penetrating behavior may be considered to be a consequence of long diagnostic delay. CD patients with long diagnostic delay may tend to develop penetrating disease behavior because of the sustained progression of the disease behavior over time [1,2]. As for this issue, a few studies have evaluated the factors associated with the diagnostic delay of CD. In a Swiss
IBD cohort study by Vavricka et al., younger age at first diagnosis (<40 years) and ileal involvement were significantly associated with a long diagnostic delay (≥24 months) [8]. A French cohort study reported that no medical and socioeconomic characteristics affected the long diagnostic delay of CD [9]. A recent study in Chinese CD patients indicated older age at diagnosis (>40 years), a basic education status, and no family history of CD were risk factors for a long diagnostic delay [10]. The results of these studies are not comparable to our results. This discrepancy may be influenced by differences in the epidemiologic and clinical features of CD and genetic susceptibility to CD according to patient ethnicity [13,30,32,40,41]. Further large studies across multiple ethnic groups are warranted to obtain convincing results related to clinical factors associated with a long diagnostic delay in CD patients.

Our study has several limitations. First, because of the retrospective design of this study, it may be subject to recall bias for the first CD-related symptoms and their onset. In addition, since some symptoms of CD are similar to those of IBS, it was difficult to determine the exact duration of the diagnostic delay (from the first symptoms to diagnosis) in some cases. Additionally, available data retrieved from the CONNECT study, a multicenter retrospective cohort, did not include the detailed information, such as the different diagnostic intervals (patient-related or physician-related delay) or how many doctors they had visited. Thus, in the present study, we assessed and analyzed clinical data including only the “overall diagnostic delay” (the time interval from the onset of the first symptoms to the establishment of the CD diagnosis). Second, our study lacks some important information on environmental and socioeconomic factors such as smoking habits, intake of non-steroidal anti-inflammatory drugs or oral contraceptives, and socioeconomic or educational status of the patients. In particular, previous studies have determined the harmful effects of smoking habits on disease course and the risk of recurrence or reoperation in CD patients [42–44]. Moreover, this study was not a population-based cohort study. However, considering that the majority of Korean CD patients are diagnosed and managed in tertiary medical centers in Korea [32], this CD cohort, including patients from 32 hospitals nationwide, may considerably reflect the real population of CD patients in Korea. Furthermore, since all patients were diagnosed and treated by IBD specialists, clinical data in this cohort are quite convincing.

In conclusion, this study demonstrated that a long diagnostic delay is significantly associated with an increased risk of CD-related complications such as intestinal stenosis, internal fistulas, and perianal fistulas. Moreover, older age at diagnosis (≥40 years), concomitant UGI involvement, and penetrating disease behavior are closely associated with diagnostic delay in CD patients. On the basis of these results, reducing the diagnostic delay of CD may reduce the occurrence of many disabling complications associated with CD. Thus, our results suggest that physicians should make particular efforts to increase the rate of early diagnosis and raise public awareness about the warning symptoms of CD.

Supporting Information

S1 Table. Predictive clinical factors associated with the risk of abscess formation in Korean patients with Crohn’s disease.

(S1 Table is included in the Supporting Information section.)

S2 Table. Predictive clinical factors associated with the risk of intestinal perforation in Korean patients with Crohn’s disease.

(S2 Table is included in the Supporting Information section.)

S3 Table. Predictive clinical factors associated with first disease-related abdominal surgery in Korean patients with Crohn’s disease.

(S3 Table is included in the Supporting Information section.)
Acknowledgments

We would like to thank all contributors within the CONNECT study group as follows: Joo Sung Kim (lead author, Seoul National University College of Medicine), Won Ho Kim (Yonsei University College of Medicine), Jae Hee Cheon (Yonsei University College of Medicine), Jong Pil Im (Seoul National University College of Medicine), Ji Won Kim (Seoul National University Boramae Medical Center), You Sun Kim (Inje University College of Medicine), Byong Duk Ye (University of Ulsan College of Medicine), Young-Ho Kim (Sungkyunkwan University School of Medicine), Tae Oh Kim (Haeundae Paik Hospital, Inje University College of Medicine), Hyun Soo Kim (Chonnam National University Medical School), Hyun-Soo Kim (Yonsei University Wonju College of Medicine), Young Sook Park (Eulji University School of Medicine), Geom Seog Seo (Wonkwang University College of Medicine), Hyun Joo Song (Jeju National University School of Medicine), Soon Man Yoon (Chungbuk National University Hospital), Kang-Moon Lee (St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea), Bo-In Lee (The Catholic University of Korea College of Medicine), Chang Kyun Lee (Kyung Hee University School of Medicine), Byung Ik Jang (Yeungnam University College of Medicine), Seok Won Jung (University of Ulsan College of Medicine), Sung-Ae Jung (Ewha Womans University School of Medicine), Yunho Jung (Soonchunhyang University College of Medicine), Yoon Tae Jin (Korea University College of Medicine), Chang Hwan Choi (Chung-Ang University College of Medicine), Dong Soo Han (Hanyang University College of Medicine), Kyu Chan Huh (Konyang University College of Medicine), Ji Hyun Lee (Seoul Sang Do Colorectal Hospital), Dong Il Park (Sungkyunkwan University School of Medicine), Sang Wook Kim (Chonbuk National University Medical School), Young-Eun Joo (Chonnam National University Medical School), Eun Soo Kim (Keimyung University College of Medicine), Seong Ran Jeon (Soonchunhyang University College of Medicine), Gwang Ho Baik (Hallym University College of Medicine, Chuncheon), Ja Seol Koo (Korea University College of Medicine), Hyun Joo Jung (Hallym University Dongtan Sacred Heart Hospital), Geun Am Song (Pusan National University School of Medicine), Chang Mo Moon (Ewha Womans University School of Medicine), Yoon Suk Jung (Sungkyunkwan University School of Medicine), Kwang Jae Lee (Ajou University School of Medicine), Jae Jun Park (Yonsei University College of Medicine), Kyeong Ok Kim (Yeungnam University College of Medicine), Eun Sun Kim (Korea University College of Medicine), Seong-Eun Kim (Ewha Womans University School of Medicine), Chang Soo Eun (Hanyang University College of Medicine), Sung Noh Hong (Sungkyunkwan University School of Medicine), Hoon Sup Koo (Konyang University College of Medicine). Lead author: Joo Sung Kim, Seoul National University College of Medicine, Seoul, Republic of Korea, email address: jooskim@snu.ac.kr.

Author Contributions

Conceived and designed the experiments: CMM. Analyzed the data: CMM SAJ. Wrote the paper: CMM. Acquisition of data: CMM SAJ SEK HJS YJ BDY JHC YSK YHK JSK DSH. Review and/or revision of the manuscript: CMM SAJ. Approved the final manuscript: CMM SAJ SEK HJS YJ BDY JHC YSK YHK JSK DSH.

References

1. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002; 8: 244–250. PMID: 12131607
2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiache J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777–782. PMID: 11709511
Diagnostic Delay in Korean Crohn's Disease Patients

3. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660–667. doi: 10.1016/S0140-6736(08)60304-9 PMID: 18295023

4. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574–1582. doi: 10.1038/ajg.2010.78 PMID: 20234346

5. Ye BD. Could early anti-tumor necrosis factor therapy change the prognosis of Crohn's disease? Intest Res. 2014; 12: 263–265. doi: 10.5217/ir.2014.12.4.263 PMID: 25374489

6. Perminow G, Brackmann S, Lyckander LG, Franke A, Borthue A, Rydting A, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009; 44: 446–456. doi: 10.1080/00365520802647434 PMID: 19117240

7. Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirin-Kiriyak V, Targan SR, et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol. 2000; 95: 3458–3462. PMID: 11151877

8. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 964–969. doi: 10.1002/ibd.21719 PMID: 21509908

9. Nahon S, Lahmek P, Lesgourgues B, Poupardin C, Chaussade S, Peyrin-Biroulet L, et al. Diagnostic delay in a French cohort of Crohn's disease patients. J Crohns Colitis. 2014; 8: 964–969. doi: 10.1016/j.jccl.2014.01.023 PMID: 24529804

10. Li Y, Ren J, Wang G, Gu G, Wu X, Ren H, et al. Diagnostic delay in Crohn's disease is associated with increased rate of abdominal surgery: A retrospective study in Chinese patients. Dig Liver Dis. 2015; 47: 544–548. doi: 10.1016/j.dld.2015.03.004 PMID: 25840874

11. Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014; 28: 363–372. doi: 10.1016/j.bpg.2014.04.003 PMID: 24913377

12. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013; 145: 158–165. doi: 10.1053/j.gastro.2013.04.007 PMID: 23583432

13. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010; 4: 1–14. doi: 10.5009/gnl.2010.4.1.1 PMID: 20479907

14. Cheon JH, Kim YS, Ye BD, Lee KM, Kim YH, Kim JS, et al. Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea. Intest Res. 2014; 12: 173–175. doi: 10.5217/ir.2014.12.3.173 PMID: 25349589

15. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749–753. PMID: 16698746

16. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK, et al. [Diagnostic guideline of Crohn's disease]. Korean J Gastroenterol. 2009; 53: 161–176. PMID: 19835218

17. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A: 5A–36A. PMID: 16151544

18. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013; 108: 1744–1753; quiz 1754. doi: 10.1038/ajg.2013.248 PMID: 23978953

19. Solberg IC, Vatn MH, Hoie O, Stray N, Sauer J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430–1438. PMID: 18054751

20. Song XM, Gao X, Li MZ, Chen ZH, Chen SC, Hu PJ, et al. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort. Dis Colon Rectum. 2011; 54: 1147–1154. doi: 10.1097/DCR.0b013e3182221ddc3 PMID: 21825886

21. Peyrin-Biroulet L, Billoud V, D'Haens G, Panaccione R, Feagan B, Panes J, et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012; 107: 1770–1776. doi: 10.1038/ajg.2012.117 PMID: 23211844
Diagnostic Delay in Korean Crohn’s Disease Patients

22. Rutgeerts P, Diamond RH, Baia M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006; 63: 433–442; quiz 446. PMID: 16500392

23. Oberhuber G, Stangl PC, Vogelsang H, Schober E, Herbst F, Gasche C. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch. 2000; 437: 293–297. PMID: 11037350

24. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006; 130: 650–656. PMID: 16530505

25. Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008; 43: 948–954. PMID: 19086165

26. Solberg IC, Vatn MH, Hoie O, Stray N, Sauer J, Jahnse J, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430–1438. PMID: 18054751

27. Broe PJ, Bayless TM, Cameron JL. Crohn’s disease: are enteroenteral fistulas an indication for surgery? Surgery. 1982; 91: 249–253. PMID: 7058505

28. Schoepfer AM, Safroeneva E, Vavricka SR, Peyrin-Biroulet L, Mottet C. Treatment of fibrostenotic and fistulizing Crohn’s disease. Digestion. 2012; 86 Suppl 1: 23–27. doi: 10.1159/000341961 PMID: 23051723

29. Thienpont C, Van Assche G. Endoscopic and medical management of fibrostenotic Crohn’s disease. Dig Dis. 2014; 32 Suppl 1: 35–38. doi: 10.1159/000367824 PMID: 25531351

30. Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, et al. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol. 2010; 45: 1178–1185. doi: 10.3109/003655521.2010.497936 PMID: 20560811

31. Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007; 13: 278–283. PMID: 17206722

32. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008; 14: 542–549. PMID: 17941073

33. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002; 97: 389–396. PMID: 11866278

34. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007; 12: 333–340. PMID: 17669107

35. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1: 1311–1315. PMID: 6145023

36. Raghunath A, Hungin AP, Woof D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003; 326: 737. PMID: 12676842

37. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003; 98: 2621–2626. PMID: 14687807

38. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17: 1314–1321. doi: 10.1002/ibd.21493 PMID: 21560194

39. Hall B, Holleran G, McNamara D. Small bowel Crohn’s disease: an emerging disease phenotype? Dig Dis. 2015; 33: 42–51. doi: 10.1159/000366047 PMID: 25531496

40. Cheon JH. Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. J Gastroenterol Hepatol. 2013; 28: 220–226. doi: 10.1111/jgh.12053 PMID: 23189979

41. Moon CM, Park DI, Kim ER, Kim YH, Lee CK, Lee SH, et al. Clinical features and predictors of clinical outcomes in Korean patients with Crohn’s disease: a Korean association for the study of intestinal diseases multicenter study. J Gastroenterol Hepatol. 2014; 29: 74–82. doi: 10.1111/jgh.12369 PMID: 23981141

42. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol. 2007; 13: 6134–6139. PMID: 18069751

43. Kane SV, Flicker M, Katz-Nelson F. Tobacco use is associated with accelerated clinical recurrence of Crohn’s disease after surgically induced remission. J Clin Gastroenterol. 2005; 39: 32–35. PMID: 15599207

44. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn’s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg. 2004; 187: 219–225. PMID: 14769308